Novel mechanisms of apoptosis induced by histone deacetylase inhibitors

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4460-4471

  Peart, Melissa J ^a   Tainton, Kellie M ^a   Ruefli, Astrid A ^a   Dear, Anthony E ^c   Sedelies, Karin A ^a   O'Reilly, Lorraine A ^b   Waterhouse, Nigel J ^a   Trapani, Joseph A ^a   Johnstone, Ricky W ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Gene Regulation Laboratory ^*

Author keywords

[No Author keywords available]

Indexed keywords

DEPSIPEPTIDE; FR 901228; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; OXAMFLATIN; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; WESTERN BLOTTING;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CASPASES; CELL CYCLE; CYCLIN D1; CYTOCHROME C GROUP; DEPSIPEPTIDES; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR MEMBRANES; LEUKEMIA, T-CELL, ACUTE; MITOCHONDRIA; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; TUMOR CELLS, CULTURED;

EID: 0042090495     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
2. Cory, S., and Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2: 647-656, 2002.
3. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., and Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 1: 194-202, 2001.
4. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery, 1: 287-299, 2002.
5. Juan, L. J., Shia, W. J., Chen, M. H., Yang, W. M., Seto, E., Lin, Y. S., and Wu, C. W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem., 275: 20436-20443, 2000.
6. Boyes, J., Byfield, P., Nakatani, Y., and Ogryzko, V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature (Lond.), 396: 594-598, 1998.
7. Kitamura, K., Hoshi, S., Koike, M., Kiyoi, H., Saito, H., and Naoe, T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol., 108: 696-702, 2000.
8. 3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene, 20: 1860-1872, 2001.
9. Chang, T. H., and Szabo, E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin. Cancer Res., 8: 1206-1212, 2002.
10. Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., and Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA, 98: 10833-10838, 2001.
11. Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M., and Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 18: 2461-2470, 1999.
12. Ueda, H., Manda, T., Matsumoto, S., Mukumoto, S., Nishigaki, F., Kawamura, I., and Shimomura, K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot., 47: 315-323, 1994.
13. Ekert, P. G., Silke, J., and Vaux, D. L. Caspase inhibitors. Cell Death Differ., 6: 1081-1086, 1999.
14. Kantharidis, P., El-Osta, A., deSilva, M., Wall, D. M., Hu, X. F., Slater, A., Nadalin, G., Parkin, J. D., and Zalcberg, J. R. Altered methylation of the human MDRI promoter is associated with acquired multidrug resistance. Clin. Cancer Res., 3: 2025-2032, 1997.
15. Broggini, M., Grandi, M., Ubezio, P., Geroni, C., Giuliani, F. C., and D'Incalci, M. Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochem. Pharmacol., 37: 4423-4431, 1988.
16. Geley, S., Hartmann, B. L., Kapelari, K., Egle, A., Villunger, A., Heidacher, D., Greil, R., Auer, B., and Kofler, R. The interleukin 1β-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. FEBS Lett., 402: 36-40, 1997.
17. INK4A sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels. J. Biol. Chem., 276: 10984-10989, 2001.
18. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med., 177: 195-200, 1993.
19. Johnstone, R. W., Cretney, E., and Smyth, M. J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood, 93: 1075-1085, 1999.
20. Ruefli, A. A., Smyth, M. J., and Johnstone, R. W. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood. 95: 2378-2385, 2000.
21. Waterhouse, N. J., Goldstein, J. C., von Ahsen, O., Schuler, M., Newmeyer, D. D., and Green, D. R. Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J. Cell Biol., 153: 319-328, 2001.
22. Xing, P. X., Tjandra, J. J., Stacker, S. A., Teh, J. G., Thompson, C. H., McLaughlin, P. J., and McKenzie, I. F. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol., 67: 183-195, 1989.
23. O'Reilly, L. A., Ekert, P., Harvey, N., Marsden, V., Cullen, L., Vaux, D. L., Hacker, G., Magnusson, C., Pakusch, M., Cecconi, F., Kuida, K., Strasser, A., Huang, D. C., and Kumar, S. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ., 9: 832-841, 2002.
24. Bernhard, D., Ausserlechner, M. J., Tonko, M., Loffler, M., Hartmann, B. L., Csordas, A., and Kofler, R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J., 13: 1991-2001, 1999.
25. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., and Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res., 241: 126-133, 1998.
26. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., and Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA, 93: 5705-5708, 1996.
27. Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., and Bates, S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46: 627-638, 1994.
28. Smyth, M. J., Krasovskis, E., Sutton, V. R., and Johnstone, R. W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA, 95: 7024-7029, 1998.
29. Ruefli, A. A., Bernhard, D., Tainton, K. M., Kofler, R., Smyth, M. J., and Johnstone, R. W. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int. J. Cancer, 99: 292-298, 2002.
30. Kwon, S. H., Ahn, S. H., Kim, Y. K., Bae, G. U., Yoon, J. W., Hong, S., Lee, H. Y., Lee, Y. W., Lee, H. W., and Han, J. W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem., 277: 2073-2080, 2002.
31. Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., and La Quaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res., 59: 4392-4399, 1999.
32. Lassus, P., Opitz-Araya, X., and Lazebnik, Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science (Wash. DC), 297: 1352-1354, 2002.
33. Kumar, S., and Vaux, D. L. Apoptosis. A Cinderella caspase takes center stage. Science (Wash. DC), 297: 1290-1291, 2002.
34. 2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell, 11: 2069-2083, 2000.
35. WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA, 95: 6791-6796, 1998.
36. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., and Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA, 97: 10014-10019, 2000.
37. 1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ., 9: 465-474, 1998.
38. Kim, Y. B., Ki, S. W., Yoshida, M., and Horinouchi, S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiot., 53: 1191-1200, 2000.
39. Mello, J. A., and Almouzni, G. The ins and outs of nucleosome assembly. Curr. Opin. Genet. Dev., 11: 136-141, 2001.
40. Taddei, A., Maison, C., Roche, D., and Almouzni, G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol., 3: 114-120, 2001.
41. WAF1/CIP1 by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol., 60: 828-837, 2001.
42. Bernhard, D., Skvortsov, S., Tinhofer, I., Hubl, H., Greil, R., Csordas, A., and Kofler, R. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ., 8: 1014-1021, 2001.
43. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39: 361-398, 1999.
44. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K. H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Nishino, N., Yoshida, M., and Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 62: 4916-4921, 2002.
45. Guo, Y., Srinivasula, S. M., Druilhe, A., Fernandes-Alnemri, T., and Alnemri, E. S. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J. Biol. Chem., 277: 13430-13437, 2002.
46. Huang, D. C., O'Reilly, L. A., Strasser, A., and Cory, S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J., 16: 4628-4638, 1997.
47. Furukawa, Y., Iwase, S., Kikuchi, J., Terui, Y., Nakamura, M., Yamada, H., Kano, Y., and Matsuda, M. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2-M phases and its role in cell cycle regulation. J. Biol. Chem., 275: 21661-21667, 2000.
48. Borner, C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J. Biol. Chem., 271: 12695-12698, 1996.
49. Medina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., and Zalewski, P. D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res., 57: 3697-3707, 1997.
50. Shimada, J., Kwon, H. J., Sawamura, M., and Schreiber, S. L. Synthesis and cellular characterization of the detransformation agent, (-)-depudecin. Chem. Biol., 2: 517-525, 1995.